Status: Recruiting
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a monotherapy and in combination with chemotherapy.
Participants needed: 203
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Phanes TherapeuticsUpdated: Sep 23, 2025Locations: 12
Eligibility criteria
NECs that have transformed from NSCLC are not eligible. Part A: Patients with hi... [+6]
Women who are pregnant or lactating. [+13]